Indobufen
Chemical compound
- B01AC10 (WHO)
- 2-(4-(1-Oxoisoindolin-2-yl)phenyl)butanoic acid
- 63610-08-2 Y
- 107641
- 96823 N
- 6T9949G4LZ
- D07141 Y
- ChEMBL1765292 N
- DTXSID7057789
- Interactive image
- O=C(O)C(c1ccc(cc1)N3C(=O)c2ccccc2C3)CC
InChI
- InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22) N
- Key:AYDXAULLCROVIT-UHFFFAOYSA-N N
Indobufen is a platelet aggregation inhibitor.[1] It acts as a reversible cyclooxygenase inhibitor.[2]
References
- ^ The Merck Index (12th ed.). p. 4991.
- ^ Eligini S, Violi F, Banfi C, Barbieri SS, Brambilla M, Saliola M, et al. (January 2006). "Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism". Cardiovascular Research. 69 (1): 218–26. doi:10.1016/j.cardiores.2005.07.013. PMID 16154551.
- v
- t
- e
Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
Glycoprotein IIb/IIIa inhibitors |
|
---|---|
ADP receptor/P2Y12 inhibitors | |
Prostaglandin analogue (PGI2) | |
COX inhibitors | |
Thromboxane inhibitors | |
Phosphodiesterase inhibitors | |
Other |
Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
---|---|---|---|---|---|
Factor Xa inhibitors (with some II inhibition) |
| ||||
Direct thrombin (IIa) inhibitors |
| ||||
Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e